Forbes Names Medidata CEO to “America’s Most Innovative Leaders” List
02 Outubro 2019 - 9:30AM
Business Wire
Company Celebrates 20 Years of Innovation Under
Tarek Sherif’s Leadership; Transforming Drug Development and
Clinical Trial Technology
- Medidata celebrates 20 years of innovation as the Operating
System for Life Sciences
- Company dedicates success to the support and collaboration of
employees, customers, partners, and the life science industry
Forbes named Tarek Sherif, CEO of Medidata (NASDAQ: MDSO), to
their list of “America’s Most Innovative Leaders.” Mr. Sherif
ranked among today’s top 100 most creative and successful business
minds.
“On behalf of all Medidata employees, I’m honored to be
recognized by Forbes as one of America’s Most Innovative Leaders,”
said Tarek Sherif, CEO and co-founder of Medidata. “Along with
co-founder, Glen de Vries, president of Medidata, we started
Medidata as a mission-driven company with a vision of powering
smarter treatments for healthier people. Innovation and high growth
require a team effort, and I’ve been lucky to be working with the
best people in our industry. The passion for innovation and
dedication of our employees, and the support of our customers and
partners around the world, has made us the leader in healthcare
technology. And, it is driving us to transform drug development for
the benefit of all patients.”
Medidata’s journey started in 1999 when the company
revolutionized clinical trials with Rave EDC. Today, Medidata is
the Operating System for Life Sciences, with over 1,300 customers,
5.2 million patients, and more than 18,000 clinical trials have
been conducted on the platform.
The Company’s focus on R&D and deep industry knowledge
continue to drive new, game-changing initiatives and strategic
partnerships, including:
- Acorn AI, a Medidata company: Launched in 2019,
Acorn AI leverages the company’s rich, regulatory grade clinical
data, machine learning and AI capabilities, and pharmaceutical
product development expertise to drive value for life science
companies. This includes accelerating innovation, improving time to
market for new drugs, and demonstrating value to a wide range of
stakeholders.
- Industry collaborations: Medidata partners with leading
life science influencers and regulatory bodies to solve industry
challenges and provide fresh perspectives through collaboration.
This includes partnering with a working group led by Friends of
Cancer Research, comprised of representatives from the FDA,
pharmaceutical companies, academia and patient advocacy. The group
seeks to address challenges of randomized control trials and
explore the power of using data from historical clinical trials,
such as with Medidata’s Synthetic Control ArmTM (SCA).
About Medidata
Medidata is leading the digital transformation of life sciences,
with the world's most-used platform for clinical development,
commercial, and real-world data. Powered by artificial intelligence
and delivered by industry experts, Medidata helps pharmaceutical,
biotech, medical device companies, and academic researchers
accelerate value, minimize risk and optimize outcomes. Medidata and
its companies, Acorn AI and SHYFT, serve more than 1,300 customers
and partners worldwide and empower more than 150,000 certified
users every day to create hope for millions of patients. Discover
the future of life sciences: www.medidata.com
About Acorn AI
Acorn AI is a Medidata company that represents the next horizon
of the industry leader’s 20-year mission of powering smarter
treatments and healthier people. Acorn AI is designed to make data
liquid across the entire lifecycle and to answer the most important
questions in R&D and commercialization for customers. Built
upon the Medidata platform, Acorn AI products feature one of the
industry’s largest structured, standardized clinical trial data
repository connected with real world, translational and other
datasets. For more information: www.acornai.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20191002005439/en/
Investors: Betsy Frank 917-522-4620
bfrank@medidata.com Media: Rosemarie Esposito
646-362-3017 resposito@medidata.com
Medidata Solutions (NASDAQ:MDSO)
Gráfico Histórico do Ativo
De Dez 2024 até Jan 2025
Medidata Solutions (NASDAQ:MDSO)
Gráfico Histórico do Ativo
De Jan 2024 até Jan 2025